There's still value in U.S. stocks despite the recent market rally, according to Charles Lemonides.
The chief investment officer of ValueWorks tells BNN there have been more winners and losers in this current rally.
"I think you're seeing signs of investors differentiating between winners and losers, not just risk-on, risk-off, and I think that could play out for a
Among Lemonides' picks are:
Eli Lilly (LLY-N) - For a long time, it was a growth name, he says. Lemonides sees the earnings growth stabilize, before it experiences an earnings
growth of 15 percent after 2014. "It's a great place where I think you're getting growth at a value price."
Boston Scientific (BSX-N) - Execution by management will be the catalyst for this stock's turnaround, he says. The company continues to generate more than $2 billion in sales each quarter. "There are signs that they are becoming more competitive on the execution side."